Sublingual immunotherapy for allergic rhinitis and conjunctivitis (Q38085032)

28 August 2017

0 references

Sublingual immunotherapy for allergic rhinitis and conjunctivitis (English)

1 reference

28 August 2017

1 reference

1 reference

1 reference

1

Giovanni Passalacqua

1 reference

28 August 2017

Giorgio Walter Canonica

series ordinal

4

object named as

Giorgio Walter Canonica

1 reference

28 August 2017

Valentina Garelli

2

1 reference

28 August 2017

Francesca Sclifò

series ordinal

3

1 reference

28 August 2017

language of work or name

1 reference

1 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

5

1 reference

28 August 2017

3

1 reference

28 August 2017

257-264

1 reference

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

28 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Allergic rhinitis and its impact on asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Sublingual immunotherapy: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Once daily sublingual immunotherapy without updosing--A new treatment schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Administration regimens for sublingual immunotherapy to pollen allergens: what do we know?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Towards evidence-based medicine in specific grass pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Recommendations for appropriate sublingual immunotherapy clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Specific immunotherapy in asthma: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Specific immunotherapy: beyond the clinical scores

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Oral immunotherapy for cow's milk allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Latex immunotherapy: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Randomized, double-blind, placebo-controlled clinical trial of sublingual immunotherapy in natural rubber latex allergic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

Immunological mechanisms of sublingual allergen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.157

21 January 2018

Identifiers

DOI

10.2217/IMT.12.157

1 reference

28 August 2017

1 reference